# Mass Drug Administration With Dihydroartemisinin + Piperaquine for Reducing Malaria in Southern Zambia

> **NCT02329301** · NA · COMPLETED · sponsor: **PATH** · enrollment: 2430 (actual)

## Conditions studied

- Malaria
- Malaria, Falciparum

## Interventions

- **DRUG:** MDA with DHAp (Eurartesim)
- **DRUG:** Focal MDA with DHAp (Eurartesim)

## Key facts

- **NCT ID:** NCT02329301
- **Lead sponsor:** PATH
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-09
- **Primary completion:** 2016-06
- **Final completion:** 2020-08
- **Target enrollment:** 2430 (ACTUAL)
- **Last updated:** 2020-09-16

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02329301

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02329301, "Mass Drug Administration With Dihydroartemisinin + Piperaquine for Reducing Malaria in Southern Zambia". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02329301. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*